Company data sheet · Qiagen
Qiagen, from its filings.
- Industry
- Biological Products,
- Headquarters
- Netherlands
- Ticker
- QGEN (NYSE)
- Sources
- SEC filings (1998–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Netherlands
- Data as of
- November 1, 2026
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $1.3 billion | $0.1 billion | |
| 2017 | $1.4 billion | $0 billion | |
| 2018 | $1.5 billion | $0.2 billion | |
| 2019 | $1.5 billion | −$0 billion | |
| 2020 | $1.9 billion | $0.4 billion | |
| 2021 | $2.3 billion | $0.5 billion | |
| 2022 | $2.1 billion | $0.4 billion | |
| 2023 | $2 billion | $0.3 billion | |
| 2024 | $2 billion | $0.1 billion | |
| 2025 | $2.1 billion | $0.4 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Netherlands, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.